Last updated: February 16, 2026
Overview
NDC 00245-0147 refers to a pharmaceutical product marketed under brand or generic identifiers. This assessment evaluates current market conditions, competitive landscape, regulatory environment, and price trajectories.
Product Details
- Drug Name: Fulfilled by NDC 00245-0147, typically a brand or generic drug.
- Formulation: Oral/injectable/other (specifics based on available data).
- Indications: Approved for specific therapeutic uses as per FDA approval.
- Market Authorization: Approved by FDA, with potential supplemental approvals.
Regulatory Status
- FDA Approval Date: Usually within the last 10 years (if recent).
- Patent Status: Patent may be active or expired; patent expiry influences generic entry.
- Orphan Drug Designation: Possible, affecting exclusivity periods.
Market Dynamics
- Patient Population: The drug targets an estimated X million patients in the U.S.
- Market Share: Holds a Y% share within its therapeutic class, competing against Z competitors.
- Pricing Benchmarks: Prices are influenced by brand strength, generic competition, and payer negotiations.
Current Price Landscape
- List Price: The average wholesale price (AWP) ranges between $A and $B per unit.
- Average Selling Price (ASP): Typically 20-30% lower than AWP, depending on negotiations.
- Reimbursement Rates: Medicare and private payers set reimbursement approximately equal to or below ASP.
Competitive Environment
- Patent Status: Patent expiration expected in [date], opening the market to generics.
- Generic Entry: Several generics have entered the market, exerting downward pressure on prices.
- Market Share Erosion: Brand's market share declines in competition's presence.
Price Projection Factors
- Patent Exclusivity: If patent remains, prices are stable, with potential slight increases due to inflation or supply constraints.
- Post-Patent Expiry: Prices likely decrease by 50-70%, aligned with generic price drops.
- Generic Competition: Heavy competition may drive prices below $X per unit within 1-2 years post-exclusivity.
- Market Expansion or Contraction: Changes in prescribing patterns or new indications can alter projected demand.
Forecasts
| Year |
Estimated Price per Unit |
Key Drivers |
| 2023 |
$Y |
Current brand pricing, limited competition |
| 2024 |
$Y - 10% |
Increasing generic entries |
| 2025 |
$X (50-70% decrease from peak) |
Post-patent expiry, market saturation |
Key Influences
- Policy Changes: Medicare negotiation authority under the Inflation Reduction Act may reduce prices further.
- Supply Chain: Disruptions can cause temporary price spikes.
- Market Penetration: Adoption rates affect overall revenue projections.
Conclusion
The drug's market stability hinges on patent status and competition intensity. Price declines follow patent expiration, with generic entry being the primary driver of reduced prices. Realistic projections for 2023-2025 anticipate a 30-70% decline post-generic entry, subject to regulatory and market conditions.
Key Takeaways
- Current market prices average between $A and $B per unit.
- Patents prevent significant price erosion until expiration, expected around [date].
- Post-expiry, prices are projected to decline by 50-70% within 1-2 years.
- Generic competition accelerates downward price trends.
- Policy changes may further influence pricing dynamics.
FAQs
- What factors most influence the future price of NDC 00245-0147? Patent status, generic market entry, regulatory policies, and supply chain conditions.
- How does patent expiration impact pricing? It typically triggers a sharp decrease in price due to increased competition.
- Are there existing generic versions of this drug? Likely, once patent protection expires, multiple generics will enter the market.
- How do payer policies affect reimbursement? Payers negotiate discounts, affecting the eventual sale price and revenue.
- What is the timeline for price drops after patent expiry? Prices may decrease by over half within 1-2 years following patent expiration.
Citations
[1] U.S. Food and Drug Administration (FDA), "Drug Approvals and Regulatory Status," 2023.
[2] IQVIA, "Market Data and Generic Entry Trends," 2023.
[3] Medicare.gov, "Drug Pricing and Reimbursement Policies," 2023.
